NIFTY Pharma remains resilient amid mixed market sentiment

Pharma and healthcare stocks stay in focus as investors track earnings, USFDA approvals, hospital growth, and global market pressures

NIFTY Pharma shows stable trend amid cautious market sentiment

Muted movement reflects consolidation phase as investors await earnings triggers

Gen Z split on AI as global study reveals rising tech optimism

Health innovations are viewed more positively than food and agricultural technologies

Pharma stocks face Q4 reality check amid global headwinds

Analysts expect modest revenue growth but pressure on profitability in the March quarter

Neurocrine Biosciences to acquire Soleno Therapeutics for $2.9 billion

The acquisition adds VYKAT XR (diazoxide choline), the first FDA-approved therapy for hyperphagia in Prader-Willi syndrome (PWS), a rare genetic disorder, to Neurocrine’s portfolio

US healthcare costs spark push for Ayurveda integration

Dabur sees early demand recovery, rural sales lead growth in Q3 FY26

Within India, Dabur expects its Home & Personal Care business to deliver double-digit growth,

India’s healthcare and pharma sectors recorded a total of 72 transactions valued at US$ 3.5 billion in Q3 2025: Grant Thornton Bharat

The quarter included three IPOs worth US$ 428 million and one Qualified Institutional Placement (QIP) worth US$ 88 million

Drug Hunter secures seed investment to scale drug discovery knowledge platform

Drug Hunter is already relied upon by researchers at more than 200 leading organizations, including Eli Lilly, Biogen, Merck KGaA, Isomorphic Labs, Deerfield Management

UFlex posts Q1 FY26 PAT at Rs. 58 Cr

The company’s virgin PET chips plant in Egypt, commissioned in Q4 FY25, achieved 74.8 per cent capacity utilization in its first full quarter. In India, the Panipat facility operated at 96.6 per cent utilization